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gy T cells are thought to mediate immune responses at epithelial surfaces. We have quantified and characterized hepatic and peripheral
blood gy T cells from 11 normal and 13 unresolved tumor-bearing human liver specimens. gy T cells are enriched in normal liver (6.6% of T
cells) relative to matched blood (0.9%; P = 0.008). The majority express CD4CD8 phenotypes and many express CD56 and/or CD161. In
vitro, hepatic gy T cells can be induced to kill tumor cell lines and release interferon-g, tumor necrosis factor-a, interleukin-2 and interleukin-
4. Analysis of Vg and Vy chain usage indicated that Vy3+ cells are expanded in normal livers (21.2% of gy T cells) compared to blood (0.5%;
P = 0.001). Tumor-bearing livers had significant expansions and depletions of gy T cell subsets but normal cytolytic activity. This study
identifies novel populations of liver T cells that may play a role in immunity against tumors.
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gy T cells account for small numbers of peripheral blood T
cells but accumulate at epithelial surfaces and at sites of
infection [1]. Most gy T cells are negative for CD4 and CD8
and are capable of recognizing antigen without the need for
major histocompatibility complex (MHC) restriction
(reviewed in Refs. [2,3]. Their T cell receptors (TCRs)
recognize relatively conserved structures on pathogens and
host cells including non-peptide metabolites and heat shock
proteins. Peripheral blood gy T cells can rapidly lyse antigen-
bearing target cells and can kill a range of tumor cell lines in
vitro. They also can rapidly release Th1 or Th2 cytokines
which can regulate differentiation and activation of compo-1521-6616/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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thought to bridge innate and adaptive immune responses [2,3].
Distinct subsets of gy Tcells, based on their TCR g- and y-
chain variable gene segment usage, are differentially distri-
buted in different tissues and show dramatic changes with
age. In adult humans, the Vg9Vy2 TCR is predominantly
found among peripheral blood gy T cells, whereas the
majority of intestinal gyTcells express Vy1 chains associated
with one of several g-chains [4–6]. Murine and human
studies have provided evidence that the selective accumula-
tions of gy T cell subsets at different body locations are the
result of peripheral selection and expansion by locally
expressed antigens [4,7,8]. Other studies, however, have
suggested that selection is not required to produce invariant
gy TCRs and that these rearrangements are programmed
[9,10]. Vg9Vy2 T cells recognize organic phosphoesters,
alkylamines, and nucleotide conjugates that are constitutively
expressed by host cells and microbial pathogens [11–13].
They also recognize heat shock proteins and putative tumor
antigens [14–16]. Vy1+ gy T cells can recognize the stress-
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a result of tumor transformation and virus infection [17,18]
although it appears that this recognition is not mediated by the
TCR [19]. Vy1+ Tcells have also been shown to recognize the
lipid-presenting molecule, CD1c [20].
The liver appears to have an important immunoregula-
tory role, being able to selectively induce immunity or
tolerance to antigens [21]. The adult human liver contains
several populations of lymphocytes that exhibit rapid anti-
gen-non-specific cytotoxicity and Th1/Th2 and regulatory
cytokine secretion [22–24]. These include many gy T cells.
Here, we have quantified and characterized hepatic gy T
cells from normal and tumor-bearing human liver speci-
mens, with respect to Vg and Vy-chain usage, T and NK cell
marker expression, cytokine secretion, and cytotoxic poten-
tial. Our data indicate that the liver has unique repertoires of
gy T cells that include cells capable of antitumor cytoto-
xicity in vitro and whose numbers are changed in patients
with hepatic malignancy.Materials and methods
Tissue specimens
Wedge liver biopsies (50–100 mg) were obtained from
11 healthy donor organs (8 male and 3 female; mean age
39.5 years; age range 18–63 years) at the time of liver
transplantation. Liver biochemistry and histology were
normal in all cases. Liver tissue was obtained from 13
patients undergoing resection for hepatic metastases of
colonic origin (7 male and 6 female; mean age 60.2 years;
age range 35–75 years). Wedge biopsies from tumor-bear-
ing tissue were taken approximately 10 cm from the tumor
margin and appeared histologically normal. All organ
donors and patients were negative for hepatitis A, B, C, y,
and E viruses. Ethical approval for this study was obtained
from the Research and Ethics Committee at St. Vincent’s
University Hospital, Dublin, Ireland. Single cell suspensions
of hepatic mononuclear cells (HMC) were prepared as
previously described [25]. gy T cells were isolated from
fresh HMC preparations using mAb-coated magnetic beads
(Miltenyi Biotec, Bergisch Gladbach, Germany) according
to manufacturer’s protocols. The purity of isolated fractions
was assessed by flow cytometry and only preparations with
purities of 95% or greater were used for functional studies.
Antibodies and flow cytometry
Monoclonal antibodies (mAb) specific for human CD3
(clone SK7), CD4 (SK3), CD8ah (SK1), CD56
(NCAM16.2), gyTCR (11F2), ahTCR (WT31), CD161
(DX12), IFN-g (25723.11), TNF-a (6401.1111), IL-2
(5344.1111), or IL-4 (8D4-8) were obtained from Becton
Dickinson (Oxford, UK). Unconjugated mAbs specific for
TCR V-regions Vy1 (clone 9R.12), Vy2 (Immu389), Vy3(P11.5B), Vg2-3-4 (23D12), Vg8 (R4.5), and Vg9
(Immu360) were obtained from Immunotech (Marseille,
France). The expression of these cell surface antigens by
freshly isolated HMC and peripheral blood mononuclear
cells (PBMC) was detected by mAb staining and three-color
flow cytometry (FACScan, Becton Dickinson) and analyzed
using CellQuest software (Becton Dickinson). To avoid
competition for binding sites on the gy TCR, the mAb that
recognizes all gy TCRs was not used in conjunction with
mAbs specific for individual Vgor Vy TCR chains. Instead,
cells were costainedwith the pan-gy and anti-CD3mAbs, and
anti-CD3 with individual Vgor Vy mAbs in separate tubes.
Detection of intracellular cytokines
Cytokine production by gy T cells after stimulation in
vitro was examined by flow cytometry. To eliminate non-
specific autofluorescence from other liver cell populations,
gy T cells were first purified from total HMC by immuno-
magnetic bead separation. Hepatic gy T cells (1  106 cells/
ml) were stimulated with 10 ng/ml phorbol myristate acetate
(PMA) (Sigma Co., Poole, UK) plus 1 Ag/ml ionomycin
(Sigma) for 4 h in 24-well plates at 37jC in 5% CO2. As
controls, unstimulated cells were treated similarly. Brefeldin
A (10 Ag/ml, Sigma), an inhibitor of protein translocation
from the endoplasmic reticulum to the Golgi apparatus, was
added to the cells for the 4-h incubation. Cells were then
stained with mAbs specific for surface CD3 and intracellular
IFN-g, TNF-a, IL-2, or IL-4 and detected by three-color
flow cytometry as described previously [24].
Cytotoxicity assays
Magnetic bead-purified gy T cells were used as effector
cells in cytotoxicity assays against K562 and Daudi target
cell lines. Natural cytotoxicity and lymphokine-activated
killing (LAK) were examined using gy T cells that were
precultured for 3 days in the absence or presence of 50 units/
ml IL-2, respectively. Cytotoxicity was assessed in standard
4-h 51Cr release assays using 2000 51Cr-labeled target cells
incubated with purified gy T cells at E/T ratios of 1:1, 5:1,
25:1, and 50:1 [24]. Specific lysis was calculated from the
amounts of 51Cr released into supernatants using the for-
mula: % specific lysis = (cpm of sample  cpm of
spontaneous release)  100 / (cpm of maximum release 
cpm of spontaneous release). Spontaneous release was
determined by incubating the target cells in the absence of
effector cells and maximum release was obtained by incu-
bation of targets with 0.1% Triton X-100.
Statistical analysis
Results were expressed as median and ranges. The
Spearman Rank and Mann–Whitney U tests for non-para-
metric data were used to analyze results. P values of <0.05
were considered to be significant.
Table 1
Phenotypic analysis of peripheral blood and hepatic gy T cells in 11
histologically normal liver transplant donors
Phenotype Frequency in blood Frequency in liver P value
% Range % Range
CD4 3.6 0.8–5.4 4.2 0.8–12.6
CD8 1.5 0.6–2.8 8.9 6.1–15.8 0.001
DN 92.8 91.9–98.7 85.5 79.1–92.0
CD56 38.8 21.3–57.9 38.9 21.1–58.4
CD161 36.8 9.1–59.2 36.2 17.0–54.6
T. Kenna et al. / Clinical Immunology 113 (2004) 56–6358Results
cd T cells accumulate in human liver
Flow cytometry was used to determine the frequencies of
human T cells that express the TCR gy heterodimer in 11
histologically normal donor livers and matched blood sam-
ples (Fig. 1A). For this part of the study, cells were stained
ex vivo with no prior manipulation. Fig. 1B shows that there
is a significant enrichment of gy T cells in normal human
liver relative to blood, since this TCR was found to be
expressed by a median of 0.93% (range 0.24–2.7%) of
peripheral blood CD3+ cells and 6.6% (range 4.0–13.8%) of
hepatic CD3+ cells (P = 0.008).
Phenotypic characterization of cd T cells in normal human
liver
The phenotypes of gy T cells in freshly isolated matched
liver and peripheral blood samples were further analyzed by
three-color flow cytometry. Similar to circulating gy T cells,
the majority of hepatic gy T cells were negative for CD4 and
CD8 (median 85.5%; range 79.1–92.0%; Table 1). Less than
5% of hepatic gy T cells expressed CD4 (4.2%; range 0.8–
12.6%), while a significantly higher proportion of hepatic gyFig. 1. gy T cell receptor (TCR) expression by freshly isolated human
peripheral blood and hepatic T cells. (A) Representative flow cytometry dot
plot showing ah and gy TCR expression by gated CD3+ mononuclear cells
from the blood and liver of a liver transplant donor. Numbers show the
percentages of CD3+ cells that express gy TCRs. (B) Percentages of CD3+ cells
in blood and livers of 11 liver transplant donors expressing gy TCRs. Medians
are shown as horizontal lines with standard errors as error bars. *P = 0.008.T cells were CD8+ (8.9%; range 6.1%–15.8%) compared
with those found in the circulation (1.5%; range 0.6–2.8%)
(P < 0.001; Table 1). A high proportion of both circulating
and hepatic gy T cells expressed the NK cell markers CD56
(38.9%; range 21.3–57.9% in blood and 38.8%; range 21.1–
58.4% in liver) and CD161 (36.8%; range 9.1–59.2% in
blood and 36.2%; range 17.0–54.6% in liver; Table 1).
TCR c and d chain gene segment usage
To determine whether hepatic gy T cells display any
‘tissue tropism’, we examined the expression by hepatic
and peripheral blood gy T cells of the Vg and Vy chains
that have previously been reported to be the most frequent-
ly found in blood, namely Vg2-3-4, Vg8, Vg9, Vy1, Vy2,
and Vy3 chains [26,27] (Fig. 2). The Vg2-3-4, Vg8, and
Vg9 chains were found to be expressed by similar fre-
quencies of gy T cells in blood and liver (Fig. 2A). The
majority of hepatic gy T cells expressed Vy2 chains
(56.4%; range 29.0–86.4%) as found in blood, while use
of the Vy1 chain by hepatic gy T cells (8.9%; range 3.4–
32.7%) was significantly reduced compared with that seen
in the blood (42.7%; range 5.7–74.2%; P = 0.035; Fig.
2A). Strikingly, a significant proportion of hepatic gy T
cells were found to express the Vy3 chain (21.2%; range
0–37.2%). In contrast, this y-chain is almost never
expressed by circulating lymphocytes (0.5%; range 0–
0.9%; P = 0.001; Figs. 2A and B).
Cytokine production by hepatic cd T cells
Flow cytometry was used to examine the cytokine
secretion profiles of hepatic gy T cells in response to in
vitro stimulation with PMA and ionomycin (Fig. 3). To
enhance clarity of mAb staining, gy T cells were first
positively selected from total HMC using magnetic beads.
Hepatic gy T cells displayed a strong Th1 bias. Significant
proportions (median 29.2%; range 14.6–54.9%) of hepatic
gy T cells produced IFN-g in response to stimulation in vitro
with PMA and ionomycin. Smaller proportions produced
IL-2 (12.9%; range 8.0–17.1%) or TNF-a (5.3%; range
1.4–15.6%). A median of 4.6% (2.8–6.2%) of hepatic gy T
cells produced the Th2 cytokine IL-4. In addition, 6.2%
(1.7–14.7%) of hepatic gy T cells from healthy liver
Fig. 3. Cytokine production by hepatic gy T cells. Percentages of hepatic gy
T cells that stain positive for interferon-g (IFN-g), interleukin-2 (IL-2),
tumor necrosis factor-a (TNF-a) and IL-4 which were either unstimulated
() or stimulated for 4 h with PMA and ionomycin (+). Horizontal lines
indicate medians of four individual samples.
Fig. 2. T cell receptor g and y chain usage by freshly isolated human
peripheral blood and hepatic T cells. (A) Box plots showing medians
(horizontal lines), interquartile ranges (shaded areas) and ranges (error bars)
of percentages of gy T cells in blood and livers of 11 liver transplant donors
expressing Vy1, Vy2, Vy3, Vg2-3-4, Vg8, and Vg9. *P = 0.035; **P =
0.001. (B) Representative flow cytometry dot plot showing Vy3 expression
by CD3+ T cells from the blood and liver of a liver transplant donor. The
numbers show the percentages of CD3+ T cells that express Vy3.
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while 7.3% (0.5–12.1%) of unstimulated cells produced IL-
2. This spontaneous cytokine production may be due to
background levels of in vivo activation, or alternatively, it
may be due to low level activation by the mAb-coated
magnetic beads used for gy T cell purification.
cd T cells in tumor-bearing liver
The numbers, phenotypes, and functions of hepatic and
peripheral blood gy T cells were also compared between
liver donors and patients with hepatic malignancy. Fig. 4A
shows that gy T cells are significantly expanded in the blood
of patients with hepatic malignancy (3.9% of total CD3+
cells vs. 0.9%; P = 0.008). While tumor-bearing liver also
showed increased proportions of gy T cells (10.4% vs.6.6%) this increase was not significant (P = 0.3). The
expression of the NK cell markers CD56 and CD161 by
hepatic gy T cells was increased in malignancy. CD56 was
expressed by a median of 38.9% of gy T cells from
histologically normal livers and 59.7% in malignant tissue
(P = 0.04). CD161 was expressed by 36.2% of gy T cells
from normal livers and 47.5% of gy T cell from tumor-
bearing livers (P = 0.05; Fig. 4B).
Analysis of Vg and Vy chain usage in tumor-bearing
liver revealed significantly different usage compared with
healthy liver (Fig. 4C). Tumor-bearing liver displayed
preferential usage of the Vy1 gene products (26.8% of
total gy T cells; P = 0.03), while Vy2 (21.2%) and Vy3
(9.61%) expression was significantly reduced (P = 0.03
and 0.02, respectively). While almost all gy T cells in the
blood and liver of liver transplant donors consistently
stained positive for mAbs specific for either Vy1, Vy2,
or Vy3, approximately 40% of gy T cells in tumor-bearing
livers did not stain for any of these mAbs, suggesting that
a gy T cell with a previously unrecognized TCR y-chain
is expanded in the livers of patients with hepatic malig-
nancy. No differences were seen between Vg chain usage
between normal and tumor-bearing livers (data not
shown).
Cytotoxic activity of hepatic cd T cells
gy T cells from healthy (n = 4) and tumor-bearing (n = 4)
liver samples were purified from freshly isolated HMC
using immunomagnetic beads (Fig. 5A) and used as effec-
Fig. 4. Peripheral blood and hepatic gy T cell phenotypes in patients with
hepatic malignancy. (A) Box plots showing medians (horizontal lines),
interquartile ranges (shaded areas) and ranges (error bars) of percentages of
CD3+ T cells in blood and livers of 11 histologically normal and 13 tumor-
bearing liver specimens that express gy T cell receptors. (B and C)
Expression of CD56, CD161 and CD8 (B) and Vy1, Vy2 and Vy3 T cell
receptor chains (C) by gy T cells from the livers of 11 histologically normal
and 13 tumor-bearing liver specimens. *P < 0.05 in all cases.
Fig. 5. Hepatic gy T cells are capable of lymphokine-activated killing of
K562 and Daudi target cells. (A) Representative flow cytometry histogram
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cells. When freshly isolated gy T cells were used as
effectors, they were unable to lyse either target cell line
(Fig. 5B). However, after incubation for 3 days with 50
units/ml IL-2, gy T cells from both normal and tumor-
bearing livers exhibited cytotoxicity against K562 and
Daudi targets (Fig. 5B), indicating that hepatic gy T cell
population contain precursors of LAK cells. No significant
difference in the cytotoxic activity of gy T cells from normal
or tumor-bearing livers against K562 or Daudi target cells
was observed.showing gy T cell receptor (TCR) expression by magnetic bead isolated
hepatic gy T cells (shaded histogram) and unseparated hepatic mononuclear
cells (unshaded). The number indicates the purity of the gy T cell
preparation. (B) Natural cytotoxicity (no IL-2) and lymphokine activated
killing (+IL-2) of K562 and Daudi target cells by magnetic bead-purified gy
T cells. The figure is representative of experiments using four histologically
normal and four tumor-bearing liver samples.Discussion
gy T cells are present in significant numbers in the
epithelia of the small intestine, skin, lungs and the pregnantuterus but they represent only a small proportion (<5%) of
the T cells in peripheral blood [2,3]. The results of the
present study indicate that the adult liver also is a site of
accumulation of gy T cells and that this organ has a distinct
distribution of the most common TCR g- and y-chains. The
majority of hepatic gy T cells express double-negative
CD4CD8 phenotypes in keeping with their ability to
recognize antigen without the need for MHC-restriction, but
CD4+ and CD8+ gy T cells were also seen. A significant
proportion express the NK cell-associated receptors (NKR)
CD56 and CD161. Hepatic gy T cells can be induced by
culture with IL-2 to kill the tumor cell lines, K562 and
Daudi, and upon activation in vitro, they produce a range of
cytokines, including IFN-g, TNF-a, IL-2, and IL-4.
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unrestricted cytotoxicity and rapid cytokine secretion ac-
count for about one third of all hepatic lymphocytes but
<5% of peripheral blood lymphocytes [22–24]. These
include CD1d-restricted NKT cells with invariant ah TCRs
that recognize lipid antigens [28,29]. Here, we show that
they also include gy T cells. Thus, multiple types of semi-
invariant T cells that mediate immediate and regulatory
immune functions accumulate in the liver.
In contrast to the human ah TCR repertoire, the germline
encoded gy TCR repertoire is small [26,30,31]. As previ-
ously reported [4,26,27], we found that almost all peripheral
blood and hepatic gy T cells are positive for either Vg2-3-4,
Vg8, or Vg9 and either Vy1, Vy2, or Vy3 TCR chains. In
both tissues, the majority (usually between 50% and 90%)
of gy T cells express Vg9 and Vy2. However, we found that
Vy3+ T cells account for approximately 20% of hepatic gy T
cells but only about 0.5% of peripheral gy T cells in healthy
individuals. The reason for the extensive use of the Vy3
element in the liver is unclear. It is known that the Vy3 gene
segment frequently recombines with Ja and Ca gene seg-
ments and that the Vy3 TCR chain does not appear to
selectively pair with any particular Vg chain [26]. gy TCR
rearrangements occur early in childhood and particular gy T
cell subsets accumulate at particular body locations with age
[4–6]. Such accumulations may be programmed [9,10] or
antigen-driven [7,8,27] and if the latter is true, the Vy3 TCR
chain is likely to respond to an antigen found in the liver.
Vy3+ T cells are reported to expand in the peripheral blood
of renal transplant recipients that develop cytomegalovirus
infection [27]. It is unknown whether Vy3+ T cells have
functions that are different from those of other gy T cells but
previous studies have suggested that different gy T cells
subsets have distinct cytokine secretion patterns [3]. While
the biased usage of gy TCRs in the liver will reflect a
distinct specificity of antigen recognition by gy T cells,
future studies using purified Vy3+ T cells are required to
identify their functions.
There is a large body of evidence to suggest that gy T
cells play a role in host defence against tumors [32,33]. gy T
cells display antitumor cytotoxicity in vitro [34–36].
Vg9Vy2+ T cells recognize antigens found on myeloma
and lymphoma cells [15,16] and Vy1+ T cells receive
costimulatory signals through NKG2D, a receptor for the
nonclassical MHC class I-molecule, MICA, which is upre-
gulated on tumor cells of epithelial origin [17,18]. gy T cells
are present among tumor infiltrating lymphocytes in breast
carcinoma [37,38], renal carcinoma [39] pancreatic cancer
[40], epithelial tumors [41], melanoma, and sarcoma [42].
Additionally, different patterns of Vy gene rearrangement
have been observed in paired blood and tumor-infiltrating
lymphocyte samples from patients with different cancers
[43]. Seki et al. [44,45] reported that activated gy T cells
accumulate in the livers of mice and humans with tumors.
We have found small overall expansions of gy T cells
expressing NKRs in the blood and livers of patients withhepatic malignancy. However, on examination of gy T cell
subsets, we found that the proportions of hepatic gy T cells
expressing the Vy1+ TCR chain, thought to play a role in the
response to epithelial tumors [17,18], are significantly
expanded in the liver. Vy1+ T cells are also expanded in
the livers of patients with chronic hepatitis C virus infection
[46], a condition that carries an increased risk of developing
hepatocellular carcinoma. In contrast, Vy2+ cells which are
the most abundant hepatic gy T cell subset, and Vy3+ cells
which appear to be unique to the liver were found in
significantly lower frequencies in tumor-bearing livers.
Interestingly, the proportions of gy T cells expressing
Vy1, Vy2, or Vy3 TCR chains in the blood and liver of
liver transplant donors consistently added up to approxi-
mately 100%, but approximately 40% of gy T cells in
tumor-bearing livers did not stain positive for any of these
mAbs, suggesting that a gy T cell with a previously
unrecognized TCR y-chain is expanded in the livers of
patients with hepatic malignancy. It is unclear from the
present study whether the decreases in Vy2+ and Vy3+ cell
numbers in tumor-bearing livers are a result of influxes or
expansions of Vy1+ and other gy T cells. It is possible that
changes in the numbers of gy T cell subsets may either
predispose an individual to metastatic liver disease or occur
in response to the tumor. Although the proportions of gy T
cell subsets were different in histologically normal and
tumor-bearing livers, total gy T cells purified from these
tissues displayed similar LAK cytotoxic activities against
K562 and Daudi targets in vitro.
In conclusion, the results of the present study provide
further evidence for the presence of cytotoxic and Th1/Th2
cytokine-releasing T cells with semi-invariant TCRs in the
adult human liver. Hepatic gy T cells are predominantly
Th1-like cells and show biased TCR usage compared to
blood. Our data suggest a role for hepatic gy T cells in
immunity against tumors.Acknowledgments
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